Lavoué Vincent, Vigneau Cécile, Duros Solène, Boudjema Karim, Levêque Jean, Piver Pascal, Aubard Yves, Gauthier Tristan
1 Department of Gynecology, Rennes University Hospital, Rennes, France. 2 Faculty of Medicine, University of Rennes 1, Rennes, France. 3 ER 440, OSS, CRLCC Eugène Marquis, Rennes, France. 4 Department of Nephrology, Hôpital Pontchaillou, Rennes University Hospital, Rennes, France. 5 Institute for Environmental, Health and Labor Research (IRSET), Rennes, France. 6 Rennes University Hospital, Department of Liver Surgery, Hôpital Pontchaillou, Rennes, France. 7 Department of Gynecology and Obstetrics, Hôpital Mère-Enfant, CHU Dupuytren, Limoges, France. 8 Pharmacology, Toxicology and Drug Safety Monitoring, INSERM, Limoges, France.
Transplantation. 2017 Feb;101(2):267-273. doi: 10.1097/TP.0000000000001481.
The aim of this systematic review was to evaluate and compare the pros and cons of using living donors or brain-dead donors in uterus transplantation programs, 2 years after the first worldwide live birth after uterus transplantation.
The Medline database and the Central Cochrane Library were used to locate uterine transplantation studies carried out in human or nonhuman primates. All types of articles (case reports, original studies, meta-analyses, reviews) in English or French were considered for inclusion.
Overall, 92 articles were screened and 44 were retained for review. Proof of concept for human uterine transplantation was demonstrated in 2014 with a living donor. Compared with a brain-dead donor strategy, a living donor strategy offers greater possibilities for planning surgery and also decreases cold ischemia time, potentially translating into a higher success rate. However, this approach poses ethical problems, given that the donor is exposed to surgery risks but does not derive any direct benefit. A brain-dead donor strategy is more acceptable from an ethical viewpoint, but its feasibility is currently unproven, potentially owing to a lack of compatible donors, and is associated with a longer cold ischemia time and a potentially higher rejection rate.
The systematic review demonstrates that uterine transplantation is a major surgical innovation for the treatment of absolute uterine factor infertility. Living and brain-dead donor strategies are not mutually exclusive and, in view of the current scarcity of uterine grafts and the anticipated future rise in demand, both will probably be necessary.
本系统评价的目的是在子宫移植后全球首例活体分娩2年后,评估和比较子宫移植项目中使用活体供体与脑死亡供体的利弊。
使用Medline数据库和Cochrane中央图书馆查找在人类或非人灵长类动物中进行的子宫移植研究。纳入所有英文或法文的文章类型(病例报告、原始研究、荟萃分析、综述)。
总体而言,筛选了92篇文章,保留44篇进行综述。2014年通过活体供体证明了人类子宫移植的概念验证。与脑死亡供体策略相比,活体供体策略为手术规划提供了更大的可能性,还减少了冷缺血时间,这可能转化为更高的成功率。然而,这种方法存在伦理问题,因为供体面临手术风险但没有获得任何直接益处。从伦理角度来看,脑死亡供体策略更易被接受,但其可行性目前尚未得到证实,这可能是由于缺乏匹配的供体,并且与更长的冷缺血时间和潜在更高的排斥率相关。
该系统评价表明,子宫移植是治疗绝对子宫因素不孕症的一项重大外科创新。活体供体和脑死亡供体策略并非相互排斥,鉴于目前子宫移植物的稀缺以及预期未来需求的增加,两者可能都是必要的。